{
    "id": 27588,
    "cites": 30,
    "cited_by": 0,
    "reference": [
        "Acemoglu, D., and J. Linn. 2004. Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics 199:1049\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c1090.",
        "Amoresano, G. V. 2007. Branded drug reformulation: The next brand vs. generic antitrust battleground. Food and Drug Law Journal 62:249\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c56.",
        "Baker, M., R. Ruback, and J. Wurgler. 2007. Behavioral Corporate Finance: A Survey. In E. Eckbo (ed.), The Handbook of Corporate Finance: Empirical Corporate Finance. Elsevier/North Holland.",
        "Berndt, E. R., P. M. Danzon, and G. B. Kruse. 2007. Dynamic competition in pharmaceuticals: Cross-national evidence from new drug diffusion. Managerial and Decision Economics 28:231\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c250.",
        "Branstetter, L., C. Chatterjee, and M. J. Higgins. 2014. Starving (or Fattening) the Golden Goose?: Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation. Working Paper 20532, National Bureau of Economic Research. URL http://www.nber. org/papers/w20532.",
        "Branstetter, L., C. Chatterjee, and M. J. Higgins. 2016. Regulation and welfare: Evidence from Paragraph IV generic entry in the pharmaceutical industry. The RAND Journal of Economics 47:857\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c890.",
        "Bulow, J. 2004. The gaming of pharmaceutical oatents. Innovation Policy and the Economy 4:145\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c187.",
        "Campello, M., J. R. Graham, and C. R. Harvey. 2010. The real effects of financial constraints: Evidence from a financial crisis. Journal of financial Economics 97:470\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c487.",
        "Dubois, P., O. d. Mouzon, F. Scott-Morton, and P. Seabright. 2015. Market size and pharmaceutical innovation. The RAND Journal of Economics 46:844\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c871.",
        "Ellison, G., and S. F. Ellison. 2011. Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. AEJ: Microeconomics 3:1\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c36.",
        "Federal Trade Commission. 2002. Generic Drug Entry Prior to Patent Expiration: An FTC Study. U.S. Government Printing Office, Washington, D.C. Frank, R. G., and D. S. Salkever. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics & Management Strategy 6:75\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c90.",
        "Gormley, T. A., and D. A. Matsa. 2011. Growing out of trouble? Corporate responses to liability risk. The Review of Financial Studies 24:2781\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c2821.",
        "Grabowski, H. G., and M. Kyle. 2007. Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics 28:491\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c502.",
        "Hadlock, C. J., and J. R. Pierce. 2010. New evidence on measuring financial constraints: Moving beyond the KZ index. The Review of Financial Studies 23:1909\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c1940.",
        "Hemphill, C. S., and B. N. Sampat. 2011. When do generics challenge drug patents? Journal of Empirical Legal Studies 8:613\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c649.",
        "Hemphill, C. S., and B. N. Sampat. 2012. Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics 31:327\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c39.",
        "Higgins, M. J., and S. J. H. Graham. 2009. Balancing innovation and access: Patent challenges tip the scales. Science 326:370\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c371.",
        "IMS Institute for Healthcare Informatics. 2016. Price Declines After Branded Medicines Lose Exclusivity in the US. Tech. rep.",
        "Lemley, M. A., and C. Shapiro. 2005. Probabilistic patents. Journal of Economic Perspectives 19:75\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c98.",
        "Modigliani, F., and M. H. Miller. 1958. The cost of capital, corporation finance and the theory of investment. American Economic Review 48:261\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c297.",
        "Morton, F., A. Stern, and S. Stern. 2018. The impact of the entry of biosimilars: Evidence from Europe. Review of Industrial Organization 53:73\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c210.",
        "Mossinghoff, G. J. 1999. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food and Drug Law Journal 54:187\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c94.",
        "Murphy, S. 2017. Essays in Pharmaceutical Economics. Ph.D. thesis, MIT Dissertation: Chapter 2.",
        "Myers, S., and N. Majluf. 1984. Corporate financing and investment decisions when firms have information that investors do not have. Journal of Financial Economics 13:187\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c217.",
        "Palermo, V., M. J. Higgins, and M. Ceccagnoli. 2019. How reliable is the market for technology ? Review of Economics and Statistics 101:107\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c120.",
        "Panattoni, L. E. 2011. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Journal of Health Economics 30:126\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c145.",
        "Prajapati, V., and H. Dureja. 2012. Product lifecycle management in pharmaceuticals. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing 12:150\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c 158.",
        "Reiffen, D., and M. R. Ward. 2005. Generic drug industry dynamics. Review of Economics and Statistics 87:37\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c49.",
        "Stein, J. C. 1996. Rational capital budgeting in an irrational world. Journal of Business 69:429\u00c3\u0083\u00c2\u00a2\u00c3\u0082\u00e2\u0082\u00ac\u00c3\u0082\u00e2\u0080\u009c455.",
        "Voet, M. 2016. The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-cycle Management. Universal-Publishers."
    ]
}